Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
NCT06053021Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of aspirin, clopidogrel, cilostazol and dipyridamole in ischemic stroke and Transient Ischemic Attack (TIA), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 90-day Composite events. Started Sep 2023; status: recruiting.
02
Drugs
aspirinclopidogrelcilostazoldipyridamole
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06053021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053021.